GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States.
FAIL · Does not pass the screen
3.49 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price3.49 USD at the 5 Nov 2026 close
Our value readUndervalued vs our fair value, as of 5 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price3.49 USD
Fair value5.00
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-11Read Accumulation3.38+3.3% to today ✓Markdown gives way to Accumulation first Accumulation read since July
2026-10-02Read Markdown3.38+3.3% to today Markup gives way to Markdown after a 9% slide in 5 weeks
2026-08-30Read Markup3.72-6.2% to today Accumulation gives way to Markup after an 18% rise in 4 weeks
2026-07-31Read Accumulation3.14+11.1% to today ✓Markup gives way to Accumulation after an 18% rise in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
GoodRx Holdings, Inc. holds its Accumulation at $3.49. Consolidating, no directional conviction, held for 40 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 40 days
Price at the screen
$3.49
Valuation
56.33 trailing · 9.48 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.60
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
38.66%
Below 33%
Interest-bearing debt is 38.7% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
35.44%
Below 49%
Money owed to the company is 35.4% of assets, under the 49% limit.
Pass
Revenue purity
1.37%
Below 5%
Only 1.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
GoodRx Holdings,'s business is in a permissible area, but its interest-bearing debt is about 39% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when GDRX's ethical verdict changes
Today GDRX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 26% discount to our $5.00 fair value.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 30.2% discount to the base estimate.
Where our models see it going: fair-value estimate $5.00, with a range of $5.00 to $7.44, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Drug savings platform stuck with flat growth
Every time someone hunts for a cheaper prescription, GoodRx sits in the middle showing options. Yet revenue is shrinking 4 percent a year and profit margins sit at just 3 percent, with return on equity also at 3 percent. The shares trade at 8.8 times forward earnings and the market assigns no meaningful opportunity despite an ethical screen pass.
We pass because low returns and negative growth leave little room for meaningful improvement even at a modest valuation. Fair value sits only 19 percent above the current price and analyst targets cluster at the same level, offering no real margin of safety once execution risk is considered.
Competition from bigger health platforms and pharmacy chains can easily squeeze what little pricing power remains. The business model depends on steady user growth that has simply stopped. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GDRX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Accumulation$3.49+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it hold, with a mean price target of $3. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$3.49+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it hold, with a mean price target of $3. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$3.49-1.4%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it hold, with a mean price target of $3. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$3.54+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it hold, with a mean price target of $3. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$3.54+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it hold, with a mean price target of $3. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$3.54+2.6%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it hold, with a mean price target of $3. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$3.45+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it hold, with a mean price target of $3. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$3.45+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it hold, with a mean price target of $3. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$3.45+2.1%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it hold, with a mean price target of $3.
2026-10-11Accumulation · changed$3.38+0.0%Entry 7
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 44%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (13 analysts) rates it hold, with a mean price target of $3.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.